Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside

0560548 - ÚMCH 2023 CH eng M - Monography Chapter
Operti, M. C. - Bernhardt, A. - Sincari, Vladimir - Jäger, Eliezer - Grimm, S. - Engel, A. - Hrubý, Martin - Figdor, C. G. - Tagit, O.
Industrial scale manufacturing and downstream processing of PLGA-based nanomedicines suitable for fully continuous operation.
Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside. Basel: MDPI, 2022 - (Tagit, O.), s. 103-120. ISBN 978-3-0365-4490-8
EU Projects: European Commission(XE) 686089 - PRECIOUS
Institutional support: RVO:61389013
Keywords : PLGA * poly(lactic-co-glycolic acid) * nanomedicine
OECD category: Polymer science
Method of publishing: Open access
https://www.mdpi.com/books/book/5741

Despite the efficacy and potential therapeutic benefits that poly(lactic-co-glycolic acid) (PLGA) nanomedicine formulations can offer, challenges related to large-scale processing hamper their clinical and commercial development. Major hurdles for the launch of a polymeric nanocarrier product on the market are batch-to-batch variations and lack of product consistency in scale-up manufacturing. Therefore, a scalable and robust manufacturing technique that allows for the transfer of nanomedicine production from the benchtop to an industrial scale is highly desirable. Downstream processes for purification, concentration, and storage of the nanomedicine formulations are equally indispensable. Here, we develop an inline sonication process for the production of polymeric PLGA nanomedicines at the industrial scale. The process and formulation parameters are optimized to obtain PLGA nanoparticles with a mean diameter of 150 ± 50 nm and a small polydispersity index (PDI < 0.2). Downstream processes based on tangential flow filtration (TFF) technology and lyophilization for the washing, concentration, and storage of formulations are also established and discussed. Using the developed manufacturing and downstream processing technologies, production of two PLGA nanoformulations encasing ritonavir and celecoxib was achieved at 84 g/h rate. As a measure of actual drug content, encapsulation efficiencies of 49.5 ± 3.2% and 80.3 ± 0.9% were achieved for ritonavir and celecoxib, respectively. When operated in-series, inline sonication and TFF can be adapted for fully continuous, industrial-scale processing of PLGA-based nanomedicines.
Permanent Link: https://hdl.handle.net/11104/0335286